0000899243-18-019717.txt : 20180710 0000899243-18-019717.hdr.sgml : 20180710 20180710181016 ACCESSION NUMBER: 0000899243-18-019717 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180706 FILED AS OF DATE: 20180710 DATE AS OF CHANGE: 20180710 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Calhoun Lesley Ann CENTRAL INDEX KEY: 0001730866 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 18947738 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC. STREET 2: 171 OYSTER POINT BOULEVARD, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 171 OYSTER POINT BLVD, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 171 OYSTER POINT BLVD, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-07-06 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001730866 Calhoun Lesley Ann C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 2018-07-06 4 M 0 1000 22.00 A 1388 D Common Stock 2018-07-06 4 S 0 1000 44.005 D 388 D Common Stock 2018-07-09 4 M 0 2295 22.00 A 2683 D Common Stock 2018-07-09 4 S 0 2295 44.274 D 388 D Stock Option (Right to Buy) 22.00 2018-07-06 4 M 0 1000 0.00 D 2026-08-14 Common Stock 1000 29000 D Stock Option (Right to Buy) 22.00 2018-07-09 4 M 0 2295 0.00 D 2026-08-14 Common Stock 2295 26705 D The Stock Option becomes exercisable with respect to 1/4th of the underlying shares on August 15, 2017 and with respect to an additional 1/12th of the underlying shares each quarter thereafter until fully vested on August 15, 2020, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Vice President, Finance and Principal Accounting Officer /s/ Lesley Ann Calhoun 2018-07-10